Medpace (NASDAQ:MEDP) VP Sells $10,890,000.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 18,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $605.00, for a total value of $10,890,000.00. Following the completion of the sale, the vice president directly owned 47,500 shares of the company’s stock, valued at $28,737,500. The trade was a 27.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Stock Up 0.5%

MEDP traded up $3.26 during midday trading on Wednesday, reaching $606.03. The company had a trading volume of 42,445 shares, compared to its average volume of 418,379. The company has a market cap of $17.07 billion, a P/E ratio of 42.38, a P/E/G ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $625.00. The business has a 50-day moving average of $532.82 and a two-hundred day moving average of $418.36.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Institutional Investors Weigh In On Medpace

Institutional investors and hedge funds have recently bought and sold shares of the business. Quent Capital LLC acquired a new stake in shares of Medpace in the third quarter valued at approximately $25,000. Optiver Holding B.V. acquired a new position in Medpace in the third quarter valued at approximately $27,000. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Brooklyn Investment Group increased its position in Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the period. Finally, Whittier Trust Co. lifted its stake in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the period. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on MEDP. Mizuho raised their price target on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a report on Friday, October 24th. Truist Financial set a $555.00 price objective on shares of Medpace in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and increased their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, Robert W. Baird set a $613.00 price target on Medpace in a report on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $475.90.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.